Brian Skorney
Stock Analyst at Baird
(2.14)
# 2,805
Out of 4,886 analysts
111
Total ratings
46.15%
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $8.39 | +281.41% | 2 | Jun 18, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $60 → $30 | $19.03 | +57.65% | 10 | Jun 17, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $102 → $105 | $85.26 | +23.15% | 4 | May 8, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $134.46 | +89.65% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $547.75 | +7.17% | 15 | Apr 30, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $60 → $57 | $13.94 | +308.90% | 3 | Apr 28, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $50 → $55 | $50.25 | +9.46% | 5 | Feb 27, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $95 → $100 | $111.06 | -9.96% | 3 | Feb 12, 2025 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $30 | $12.65 | +137.15% | 1 | Dec 13, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $14 → $5 | $0.37 | +1,255.01% | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $7.79 | +156.90% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.48 | +618.39% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $10 | $2.50 | +300.00% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $297.00 | -27.61% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $128.74 | +39.82% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $4.44 | +531.34% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $62 | $29.38 | +111.06% | 4 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $8.74 | +346.22% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $31.42 | +100.51% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $466.36 | -30.31% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $16.87 | -40.72% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $2.46 | +10,875.61% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $3.18 | +88.68% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $1.85 | +16,116.22% | 3 | May 7, 2018 |
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $8.39
Upside: +281.41%
Sarepta Therapeutics
Jun 17, 2025
Maintains: Outperform
Price Target: $60 → $30
Current: $19.03
Upside: +57.65%
Soleno Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $102 → $105
Current: $85.26
Upside: +23.15%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $134.46
Upside: +89.65%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $547.75
Upside: +7.17%
Biohaven
Apr 28, 2025
Maintains: Outperform
Price Target: $60 → $57
Current: $13.94
Upside: +308.90%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50 → $55
Current: $50.25
Upside: +9.46%
Gilead Sciences
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $111.06
Upside: -9.96%
Benitec Biopharma
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $12.65
Upside: +137.15%
Applied Therapeutics
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.37
Upside: +1,255.01%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $7.79
Upside: +156.90%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $3.48
Upside: +618.39%
Oct 23, 2024
Maintains: Outperform
Price Target: $32 → $10
Current: $2.50
Upside: +300.00%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $297.00
Upside: -27.61%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $128.74
Upside: +39.82%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $4.44
Upside: +531.34%
May 23, 2024
Maintains: Outperform
Price Target: $52 → $62
Current: $29.38
Upside: +111.06%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $8.74
Upside: +346.22%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $31.42
Upside: +100.51%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $466.36
Upside: -30.31%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $16.87
Upside: -40.72%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $2.46
Upside: +10,875.61%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $3.18
Upside: +88.68%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $1.85
Upside: +16,116.22%